HOME > TOP STORIES
TOP STORIES
-
REGULATORY LDP Study Group Shows Sense of Crisis over Reduction of R&D Tax Deduction Cap
December 25, 2014
-
ORGANIZATION FPMAJ “Hasn’t Given Up” on Maintenance of 30% R&D Tax Deduction Cap: Chairman
December 24, 2014
-
ORGANIZATION EFPIA Japan Chairman Calls for More Rewards for Innovation
December 22, 2014
-
BUSINESS Takeda Names Sanofi’s Plump as New R&D Head
December 19, 2014
-
BUSINESS Daiichi Sankyo Looks to Bring Annual 8-10 Projects into Clinical Phase, Open Innovation Key to Success: R&D Execs
December 18, 2014
-
BUSINESS CRO Intellim to Collaborate with Indian Firm for CDISC
December 18, 2014
-
REGULATORY LDP Tax Panel Execs Eye Slight Cut of R&D Tax Deduction Cap
December 17, 2014
-
BUSINESS Battle Begins for Blopress Generics
December 16, 2014
-
REGULATORY LDP Healthcare Big Names Cruise to Victory in Lower House Poll
December 15, 2014
-
REGULATORY Outline of New Global Clinical Trial Guidelines Agreed On at ICH Confab in Lisbon
December 12, 2014
-
REGULATORY Elplat, Elaspol Generics to Join NHI Price List on Dec. 12
December 11, 2014
-
REGULATORY Annual NHI Price Cuts Draw Fire from All Sides at Ryukaikon Council
December 10, 2014
-
REGULATORY Japan NIH to Have Drug Discovery Support Unit
December 9, 2014
-
BUSINESS April-September Sales Drop 21.5% for Major Long-Listed Products
December 8, 2014
-
BUSINESS Daiichi Sankyo to Harness Ties with Cardiologists in Lixiana Promotion
December 8, 2014
-
BUSINESS Nippon Chemiphar to Set Up Plant in Vietnam, Operation Launch Slated in 2018
December 5, 2014
-
REGULATORY ICH Makes Progress Toward Greater Inclusivity, Agrees to Establish Assembly at November Meeting in Lisbon
December 4, 2014
-
REGULATORY Pharma Industry Girding for Post-Election Lobbying on R&D Tax Credit
December 3, 2014
-
BUSINESS Otsuka to Buy US Firm Avanir Pharmaceuticals to Fully Enter Neurology Market
December 3, 2014
-
BUSINESS Takeda’s Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by US FDA
December 3, 2014
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
